Dextrothyroxine
Choloxin (dextrothyroxine) is a small molecule pharmaceutical. Dextrothyroxine was first approved as Choloxin on 1982-01-01. It is used to treat coronary artery disease, hypercholesterolemia, and hyperlipoproteinemias in the USA. The pharmaceutical is active against thyroid hormone receptor beta and thyroid hormone receptor alpha.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dextrothyroxine sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CHOLOXIN | AbbVie | N-012302 DISCN | 1982-01-01 | 4 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| coronary artery disease | — | D003324 | I25.1 |
| hypercholesterolemia | HP_0003124 | D006937 | — |
| hyperlipoproteinemias | — | D006951 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
82 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | 7 | 5 | 5 | 4 | 19 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | 2 | — | 1 | 1 | 4 |
| Conduct disorder | D019955 | EFO_0004216 | F91 | — | — | — | 2 | — | 2 |
| Cognitive dysfunction | D060825 | G31.84 | — | 1 | 1 | 1 | — | 2 | |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | — | 1 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | 1 | — | 1 |
| Motivation | D009042 | — | — | — | 1 | — | 1 | ||
| Deception | D008192 | — | — | — | 1 | — | 1 | ||
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | — | 1 | — | 1 |
| Dementia | D003704 | F03 | — | — | — | 1 | — | 1 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | F14 | 8 | 11 | 2 | — | 1 | 20 | |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 2 | 2 | — | — | 2 |
| Glioma | D005910 | EFO_0000520 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | — | — | 2 | 3 |
| Narcolepsy | D009290 | EFO_0000614 | G47.4 | 2 | 1 | — | — | — | 3 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | 1 | — | — | 1 | 2 |
| Anhedonia | D059445 | R45.84 | 1 | 1 | — | — | — | 2 | |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 1 | 1 | — | — | — | 2 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 2 | — | — | — | 2 |
| Short-term memory | D008570 | EFO_0004335 | — | 1 | — | — | — | 1 | |
| Affect | D000339 | — | 1 | — | — | — | 1 | ||
| Gambling | D005715 | F63.0 | — | 1 | — | — | — | 1 | |
| Idiopathic hypersomnia | D020177 | G47.11 | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 5 | — | — | — | — | 5 | ||
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | — | — | — | 1 | 2 |
| Hemodynamics | D006439 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psychotic disorders | D011618 | F20.81 | — | — | — | — | 1 | 1 | |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | — | — | — | 1 | 1 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | — | — | — | 1 | 1 |
| Tobacco use disorder | D014029 | F17 | — | — | — | — | 1 | 1 | |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | — | — | — | — | 1 | 1 |
| Morbid obesity | D009767 | EFO_0001074 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DEXTROTHYROXINE |
| INN | dextrothyroxine sodium |
| Description | D-thyroxine is the D-enantiomer of thyroxine. It is a thyroxine and a D-tyrosine derivative. It is an enantiomer of a L-thyroxine. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | N[C@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 51-49-0 |
| RxCUI | 3292 |
| ChEMBL ID | CHEMBL559 |
| ChEBI ID | 30659 |
| PubChem CID | 8730 |
| DrugBank | DB00509 |
| UNII ID | J60FX7V025 (ChemIDplus, GSRS) |
Target
Agency Approved
THRB
THRB
THRA
THRA
Organism
Homo sapiens
Gene name
THRB
Gene synonyms
ERBA2, NR1A2, THR1
NCBI Gene ID
Protein name
thyroid hormone receptor beta
Protein synonyms
c-erbA-2, c-erbA-beta, Nuclear receptor subfamily 1 group A member 2, oncogene ERBA2, thyroid hormone receptor, beta (erythroblastic leukemia viral (v-erb-a) oncogene homolog 2, avian)
Uniprot ID
Mouse ortholog
Thrb (21834)
thyroid hormone receptor beta (Q3TY80)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 131 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
21,079 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more